Microbot Medical Inc (MBOT)

[subslover]

Out at $3.00 bro.

[Triple nickle]

Yeah at 2.26

[Invest-in-America]

MBOT: And there it GOES!!! (Hope ya-all grabbed some earlier.)

Gonna be the OFFICIAL winner of this curious Markets day!!!

[Invest-in-America]

MBOT: Lookin' like it wants to SOAR from right here!!! (Peeps may simply like their AI & ROBOTICS gadets & stuff!!!)

[Invest-in-America]

MBOT: Me neither, Dude. (Cheap ANIMAL study; long way from anything HUMANS.)

HOWEVER!!! Since they gots lots of cute ROBOTICS stuff, well, maybe THAT's what's 'trending' on THIS particular day.

[TheFinalCD]

2.40'S

[Triple nickle]

Hmmmm not for me right now

[subslover]

MBOT
Microbot Medical Inc

Microbot Medical Inc (NASDAQ)
Search Symbol or Name

1.84
0.61 (49.59%)
Real-Time
Quote
Board
Chart
Level 2
News
Trades
OptionsNew
Financials
Public.com
Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians
May 22 2023 - 08:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Surgical Robotic System, the first single-use endovascular robotic system, today announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab.
A team of six leading European interventional radiologists utilized the system and performed a total of 48 catheterizations to pre-determined vascular targets including distal branches of hepatic, gastric, splenic, mesenteric, renal, and hypogastric arteries, with a 100% success rate of reaching the intended target.

Based on real-time user feedback, the interventional radiologists found the system intuitive, easy to set up and use, and were impressed with the ability to control procedures remotely via the LIBERTY Robotic System’s remote controller.

“The results of the multi-day study continue to validate LIBERTY and is further evidence that the on-going adjustments we have made will ensure the safety and efficacy of the system as we plan to enter the human clinical phase during the second half of the year,” commented Dr. Eyal Morag, Chief Medical Officer.

“We believe this, along with other expected opportunities for peer-reviewed publications, will lay the foundation of showing the significant benefits LIBERTY is expected to bring when commercialized and helping to accelerate early adoption,” added Dr. Eyal Morag.

The Company plans on performing pre-clinical studies in the U.S. and other target markets, as well as first-in-human case in markets outside the U.S. in preparation for the continued progression toward commercialization of the LIBERTY Surgical Robotic System.

The 48 successful catheterizations are part of the Company’s recent announcement regarding surpassing 100th catheterization during multiple pre-clinical studies, with a 95% success rate of reaching pre-determined vascular targets.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The LIBERTY Robotic System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Robotic System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company’s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michal Efraty
[phone]
[e-mail]



Primary Logo

Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to May 2023 Click Here for more Microbot Medical Charts. Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2022 to May 2023 Click Here for more Microbot Medical Charts.
Latest MBOT Messages
redspinelpinktopaz Tue Dec 28, 2021 10:27 AM (509 days ago)
Probably lead to a financing?

Pt3 Mon Dec 27, 2021 1:44 PM (510 days ago)
seller beware lol

SteevoTrader Mon Dec 27, 2021 1:01 PM (510 days ago)
Agreed

Pedro2004 Mon Dec 27, 2021 11:34 AM (510 days ago)
*** Buyer Beware ***

Pedro2004 Mon Dec 27, 2021 11:33 AM (510 days ago)
Decided to take a loss on this today.

Pedro2004 Mon Dec 27, 2021 11:20 AM (510 days ago)
Shorts don't attack a company like this...unless the

Bigbruin Mon Dec 27, 2021 10:18 AM (510 days ago)
Wow

biglued1 Fri Jul 9, 2021 1:03 AM (682 days ago)
If you played MBOT right…..you’ve made a lot

ClayTrader Mon Aug 17, 2020 5:59 PM (1007 days ago)
* * $MBOT Video Chart 08-17-2020 * *

whytestocks Mon Aug 17, 2020 11:15 AM (1007 days ago)
News: $MBOT Microbot Medical Announces Successful Animal Study

See More Posts on MBOT Message Board
News
Press Releases
All News
Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians
GlobeNewswire Inc. • Mon May 22, 2023 8:30 AM (58 minutes ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Thu May 18, 2023 9:31 AM (4 days ago)
Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases
GlobeNewswire Inc. • Thu May 18, 2023 9:15 AM (4 days ago)
Quarterly Report (10-q)
Edgar (US Regulatory) • Wed May 17, 2023 5:01 PM (5 days ago)
Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
Edgar (US Regulatory) • Tue May 16, 2023 1:10 PM (6 days ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Mon May 08, 2023 8:30 AM (2 weeks ago)
Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System
GlobeNewswire Inc. • Mon May 08, 2023 8:30 AM (2 weeks ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Fri May 05, 2023 9:01 AM (2 weeks ago)
Microbot Medical Announces Final Data From Its Recent Animal Study
GlobeNewswire Inc. • Fri May 05, 2023 9:00 AM (2 weeks ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Wed May 03, 2023 9:01 AM (3 weeks ago)
Microbot Medical’s LIBERTY® Robotic System Surpasses 100th Catheterization
GlobeNewswire Inc. • Wed May 03, 2023 9:00 AM (3 weeks ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Thu Mar 23, 2023 9:01 AM (2 months ago)
More News Articles

Microbot Medical (NASDAQ:MBOT)
Intraday Stock Chart
Monday 22 May 2023

[redspinelpinktopaz]

Probably lead to a financing?

[Pt3]

seller beware lol

[SteevoTrader]

Agreed

[Pedro2004]

*** Buyer Beware ***

Dropped from $9.35 to $8.10 in a matter of minutes.

[Pedro2004]

Decided to take a loss on this today.

[Pedro2004]

Shorts don't attack a company like this...unless the Shorts know the company is FOS and a pump.

So far, it looks like there's a combination of Insider's dumping and a short-attack.

Sucks.

[Bigbruin]

Wow

[biglued1]

If you played MBOT right…..you’ve made a lot of coin the past few years…

[ClayTrader]

* * $MBOT Video Chart 08-17-2020 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $MBOT Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY(TM) Robotic System

World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical Staff HINGH...

Got this from MBOT - Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY(TM) Robotic System

[Golden Cross]

Nice...Thanks for the headsup here

[crudeoil24]

MBOT up 42% > low float > Microbot Medical shares are trading higher after the company announced its animal study utilizing its LIBERTY robotic system met all endpoints.

[whytestocks]

News: $MBOT Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System

HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using the Company’...

Got this from MBOT - Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System

[Golden Cross]

50/200sma crossing bullish on the chart Friday. RSI getting ready to cross over bullish here also...

[run256]

Moving sideways no clear direction as to where the price should go.

[run256]

nice

[run256]

long term trend shows slight positive trend.

[ClayTrader]

* * $MBOT Video Chart 04-25-2020 * *

Link to Video - click here to watch the technical chart video

[run256]

a slight upward trend continues

[run256]

HINGHAM, Mass., April 1, 2020 – Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Aileen Stockburger to the Company's Board of Directors, effective April 1, 2020. Ms. Stockburger is an experienced executive and consultant with extensive expertise in strategizing, managing and closing sizable, complex worldwide mergers and acquisitions, licensing agreements and divestitures, as well as expertise in business development, strategic planning and finance.



“We are excited to have Aileen join us and strengthen our leadership team’s core capabilities, as her strategic track record and vast industry network will add tremendous value to the organization”, commented Harel Gadot, CEO, President and Chairman. “Her proven experience in merger and acquisition transactions as well as the formation and execution of strategic collaborations across the industry, will greatly enhance the Company’s ability to achieve its strategic growth objectives.”



During her almost 30 years at Johnson & Johnson, Ms. Stockburger held several business development and finance roles in Medical Devices, Corporate and Consumer. She served as Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities. While in that role, she played leading and significant roles in over $70 billion worth of transactions, including: Johnson and Johnson’s acquisition of Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining Johnson & Johnson, Aileen spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania



“Throughout my career I have sought out opportunities that allow me to use my specific skills to help effect meaningful change and impact to the healthcare market,” commented Ms. Stockburger. “I have watched Microbot Medical the past few years, albeit from a distance, and my enthusiasm to join the Board at this specific time is due to its progress developing highly advanced and revolutionary robotic systems that will transform the future of healthcare. I believe that my expertise, combined with Microbot’s assets and ambition, will allow us to address new and emerging growth markets.”

[run256]

The downtrend seems to be exhausting for MBOT, but general market conditions are bad. Results for SCS are due for first quarter 2020.

[stockguard]

Stay optimistic then. GLTY
click on the chart below.

insert-text-here

[run256]

Large volume today, expectations around SCS results could be the driver. 12 is an important barrier.

[ClayTrader]

* * $MBOT Video Chart 02-21-2020 * *

Link to Video - click here to watch the technical chart video

[run256]

Microbot Medical Bologna presention.

O69 Biocompatibility of the novel microbot medical SCS shunt catheter
James P McAllister II1, Leandro Castaneyra-Ruiz1, Albert M Isaacs1, Michael Talcott1,2, Simon Sharon3, Or Samoocha3, Eran Cohen3, Ian Boader3, Carolyn A Harris4, Hezi Himelfarb3
1Department of Neurosurgery, Division of Pediatric Neurosurgery, Washington University School of Medicine, St. Louis, United Sates; 2Division of Comparative Medicine, Washington University School of Medicine, St. Louis, United Sates; 3Microbot Medical Ltd, Caesarea, Israel; 4Department of Chemical Engineering, Wayne State University, Detroit, United Sates

Correspondence: James P McAllister II
Fluids and Barriers of the CNS 2018, 15(Suppl 2):O68
Introduction: Since occlusion of ventriculoperitoneal shunt (VPS) catheters continues to be a major cause of treatment failure in hydrocephalus patients, Microbot Medical, Inc. has designed the self-cleaning ventricular catheter (SCS) to resist catheter obstruction. Following promising in vitro and ex situ studies, preclinical evaluations of the SCS are needed, with an initial focus on biocompatibility.
Methods: Hydrocephalus was induced in 30-day old piglets by percutaneous intracisternal injection of 25% kaolin. After ventriculomegaly had developed for 3–44 days, standard VPS (n?=?1) and SCS (n?=?4) catheters were implanted using routine surgical procedures. The Microbot activation coil was placed into a subcutaneous pocket behind the left ear and distal catheters were tunneled subcutaneously and inserted into the peritoneal cavity. Animals were monitored for neurological deficits, ventriculomegaly, and sacrificed at 5–49 days post-shunt (median 15d). Fixed tissue blocks containing the catheter path were processed for histopathology and immunohistochemistry.
Results: Preliminary observations indicate that unactivated Microbot catheters exhibit the same neural tissue reaction as the standard commercial catheter in current clinical practice, although ventriculomegaly increased somewhat after shunting (ventricular volume 2774 mm3 vs 4051 mm3). Both types of catheters were ensheathed by a very thin capsule of collagenous and astrocytic tissue as they passed through brain tissue or contacted the ependyma. Adjacent white matter exhibited a mild inflammatory reaction that extended only 0.2–1.0 mm beyond the surface of the catheter.
Conclusions: The inflammatory reaction to the Microbot catheter appeared to be no different than the reaction to the standard catheter.

O70 Development of a piglet model of hydrocephalus for endoscopic third ventriculostomy
James P. McAllister II1, Michael Talcott2, Albert M. Isaacs1, Leandro Castaneyra-Ruiz1, Alexis Hartman1, David D. Limbrick Jr1
1Department of Neurosurgery, Division of Pediatric Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, United States; 2Division of Comparative Medicine, Washington University School of Medicine, St. Louis, Missouri, United States

Correspondence: James P. McAllister II
Fluids and Barriers of the CNS 2018, 15(Suppl 2):O69
Introduction: Large, clinically-relevant animal models of hydrocephalus in which neurosurgical devices and novel procedures could be tested are lacking. To meet this unmet need, we have developed a porcine model of juvenile obstructive hydrocephalus, and now report our experience in performing endoscopic third ventriculostomy (ETV) on this model.
Methods: Hydrocephalus was induced in 30-day old piglets by percutaneous intracisternal injections of 25% kaolin. Pre- and post-kaolin, and pre- and post-treatment (ventriculoperitoneal shunting and ETV), anatomic MRIs were obtained to document ventriculomegaly and guide the neurosurgical procedures. Animals survived 1–84 days (median 41) post-kaolin and 17 days (median 18) post-shunt; to date the ETV case was a terminal procedure.

Results: Lateral ventricle volumes progressed from 1291?+?188 mm3 SEM pre-kaolin to 2455?+?1067, 2821?+?1139, 2280?+?1836, and 3538?+?2043 at post-kaolin days 1–5, 8–15, 22–29, and 42–69, respectively. Ventriculomegaly continued to progress post-shunt (mean 4051 mm3). ETV was performed successfully using standard neurosurgical procedures; i.e. frontal approach, visualization of the foramen of Monro (FoM), and opening the floor of the 3rd ventricle with balloon expansion. The piglet survived the procedure and after brain fixation via cardiac perfusion the path through the FoM and the ETV could be confirmed grossly with minimal damage to adjacent tissue.
Conclusions: The juvenile piglet represents a good, clinically-relevant large animal model of hydrocephalus that is amenable to ventricular shunting and ETV. Cauterization of the choroid plexus also seems feasible.

[longrider51]

https://microbotmedical.gcs-web.com/news-releases/news-release-details/microbot-medical-receives-intention-grant-european-patent-office

[stockguard]

Is this all there is??????????????????????

Microbot Medical’s Self-Cleaning Shunt (SCS™) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Laboratory Study

https://www.globenewswire.com/news-release/2019/09/10/1913337/0/en/Microbot-Medical-s-Self-Cleaning-Shunt-SCS-Clearly-Demonstrated-the-Ability-to-Prevent-Shunt-Occlusion-in-a-Follow-up-In-vitro-Laboratory-Study.html

[stockguard]

Have they yet to preform any trials in vitro or otherwise or released any white papers on mice research?

I can find nothing about research just a lot of noise about an idea. Can someone direct me to ANY real research? TIA

[run256]

Price movement improving. Could be back to 10 next week.

[run256]

The company has not released results on the SCS. Possible scenarios are that the results were not as expected and the company will just not disclose them. Other thoughts, results are not ready or the results were good and the company is already discussing a deal, and is under a quiet period.

Mr Gadot seems prone to always announce advances with a lot noise.

[JAG626]

Siemens Healthineers recent acquisition of Corindus Vascular Robotics Inc shows big players will gobble up smaller companies like Liberty Microbot Medical in this medical device sector imo

[run256]

Presentation link https://microbotmedical.com/presentation-resources/

How the investment community perceives the value of Liberty will be reflected most likely in the price in the following weeks.

[run256]

Momentum around the presentation is built. Price movements after monday will reflect the first reaction over the possibilities of Liberty of becoming a success.

News on SCS can be expected anytime. Volume has been unusually high. Positive news could make the price increase further.

Closing price was neither HOD nor HOW but was a positive signal.

[ClayTrader]

* * $MBOT Video Chart 01-10-2020 * *

Link to Video - click here to watch the technical chart video

[stockguard]

This is a sell the news event. Take some profit. GLA

[run256]

Messages are to be about the company, the stock or other members opinion. Opinions about another board member thoughts, are not be addressed in a personal manner.

[all right all right]

sell me your 10s

[all right all right]

sell me your 10s

[all right all right]

sell me your 10s

[flyonthewall]

Common sense would be that the Liberty presentation on the 13th in San Francisco in front of many Medical Neuro Surgeon peers would increase buying activity in $MBOT. What makes you so Bearish and negative about it? Also check out $SECI. Billions on the line in damages decided at trial this May 2020 with a short squeeze in play.

[run256]

Expectations and anticipation will increase as the 13th is closer. So should the price. Maybe 14 to 16 price levels. Soon after, i.m.o., if news about SCS are not available the price should retest the $10 levels.

[Oger]

Not going to pop .
But thank you for your service